https://www.thebodypro.com/category/lopinavir-ritonavir-kaletra/tag/conference-coverage

The Latest

Promo Image

Long-Acting HIV Treatment: 5 Myths and Realities

Long-acting antiretrovirals: Are they the future of HIV treatment or will the future pass them by? Researcher Charles W. Flexner recently addressed several common myths.

Women on Lopinavir/Ritonavir-Based Regimens at Conception at Higher Risk of Preterm Delivery in UK Study Img

Women on Lopinavir/Ritonavir-Based Regimens at Conception at Higher Risk of Preterm Delivery in UK Study

HIV-positive pregnant women receiving lopinavir/ritonavir-based regimens were at higher risk of preterm delivery compared with those on NNRTI-based regimens.

Lopinavir/Ritonavir Superior to Nevirapine in Children Over 3 Years Old: IMPAACT P1060 Study Results Img

Lopinavir/Ritonavir Superior to Nevirapine in Children Over 3 Years Old: IMPAACT P1060 Study Results

Long-term virologic suppression was superior in children receiving lopinavir/ritonavir-based antiretroviral therapy compared with nevirapine-based regimens at five-year follow up in the IMPAACT P1060 trial.

Dual-Drug Therapy of Lopinavir/Ritonavir and Lamivudine Non-Inferior to Triple-Drug Therapy Img

Dual-Drug Therapy of Lopinavir/Ritonavir and Lamivudine Non-Inferior to Triple-Drug Therapy

A recent study revealed a surprising result: For the first time ever, an HIV treatment regimen consisting of two drugs was found to work just as well as a three-drug regimen.

Promo Image

Lopinavir/Ritonavir Monotherapy: The Answer's Still No

At IAS 2013, investigators from the EARNEST trial reported the primary outcome of their study at 96 weeks. Study details are as follows: 1,277 HIV-infected Africans with failure of their first NNRTI-based regimen were randomly assigned to one of thre...

Promo Image

Lower Malaria Risk in Children Receiving Lopinavir/Ritonavir-Based Compared to NNRTI-Based ART

Children with HIV in sub-Saharan Africa have significant morbidity and mortality risk from malaria. Interventions including bed nets and cotrimoxazole are not sufficient to decrease the risk in this population.

HIV and malaria parasites both encode ...

Promo Image

Lopinavir/Ritonavir Oral Solution Toxicity in Neonates

Lopinavir/ritonavir (LPV/r, Kaletra) oral solution is approved by the FDA for infants 14 days of age and older. US guidelines do not recommend its use in preterm infants.

LPV/r oral solution has particular pharmacokinetic properties that make its us...

Promo Image

Pharmacokinetics of Different Rifabutin Dosing Strategies With Lopinavir/Ritonavir-Based ART

Interactions between rifampicin and protease inhibitors makes treating patients coinfected with HIV and TB more complicated.

Rifabutin is an alternative rifamycin, which can be used in patients receiving a protease inhibitor. Recent findings suggest...

Promo Image

Jens Lundgren, M.D., Discusses New Findings Regarding MI Risk of Specific Antiretrovirals

While at CROI 2009, I had the chance to talk with Jens Lundgren, M.D., the chief physician and director of the Copenhagen HIV Programme. Dr. Lundgren presented new data at this conference showing that specific antiretrovirals may be associated with a...

Promo Image

ATAZIP: Switching Away From Lopinavir/Ritonavir

Switching between protease inhibitors (PIs) may lead to improved dosing frequency, better management of gastrointestinal and lipid toxicity and a reduction in ritonavir (RTV, Norvir) exposure levels. The SWAN study1 was the largest study to evaluate ...